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Statistical Analysis and Interpretation of
Prenatal Diagnostic Imaging Studies,
Part 1
Evaluating the Efficiency of Screening and Diagnostic Tests
creening and diagnostic testing play fundamental roles in
all fields of clinical medicine, with obstetric imaging and pre-
natal diagnosis being no exceptions. The term screening test
refers to a test typically performed in an asymptomatic population
to identify or assign a probability of the risk of disease to individu-
als in that population. In contrast, a diagnostic test typically refers to
a test performed in a symptomatic or high-risk population meant to
identify or confirm an affected individual.1 With this distinction in
mind, the term prenatal diagnosis should really be expanded to pre-
natal screening and diagnosis. With advances in maternal serum
screening and ultrasound technology, much research effort in the
field of prenatal diagnosis has actually been dedicated to the devel-
opment and refinement of screening tests for fetal aneuploidy and
other congenital disorders. When these screening tests yield positive
results or confer a high probability of disease, the patient is then
often referred for invasive diagnostic testing. Understanding the fea-
tures of both screening and diagnostic testing is essential to clinicians,
not only for critically interpreting study results in the literature, but
also for the practical application of these results to their patient pop-
ulations. This article aims to review the differences between screen-
ing and diagnostic tests, describe the accepted criteria for an efficient
screening test, provide an overview of the calculation and interpre-
tation of test performance characteristics in relation to prenatal
imaging studies, and discuss relevant aspects of study design to con-
sider when evaluating these tests.
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STATE-OF-THE-ART REVIEW
Screening and diagnostic testing play fundamental roles in all fields of clinical medicine,
with obstetric imaging and prenatal diagnosis being no exceptions. With advances in ma-
ternal serum screening and ultrasound technology, much research effort in the field of pre-
natal diagnosis has actually been dedicated to the development and refinement of
screening tests for fetal aneuploidy and other congenital disorders. This article aims to re-
view the differences between screening and diagnostic tests, describe the accepted crite-
ria for an efficient screening test, and provide an overview of the calculation and
interpretation of test performance characteristics in relation to prenatal imaging studies.
Key Words—diagnostic tests; receiver operating characteristic curves; screening tests;
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What Makes a Screening Test Efficient?
As is inherent in the name, a screening test is a “screen” of
an apparently healthy population to identify individuals at
high risk for disease. If a positive result is obtained, results
of that screening test are typically confirmed by a subse-
quent diagnostic test. For a screening test to be efficient,
there are certain criteria, initially established by the World
Health Organization, that should be met.2 First, the dis-
ease of interest should be important, be relatively common,
and place a substantial burden on health. Next, the screen-
ing test should be relatively easy to perform, cost-effective,
and acceptable to patients. In contrast, diagnostic tests are
often more complex, potentially invasive, and costly. An-
other criterion for a successful screening test is that an ef-
fective intervention for the disease of interest should also
exist with a generally agreed-on plan of action if a positive
test result should occur. Particularly related to prenatal ge-
netic screening, the test should be able to be performed
early enough in gestation so that the option for pregnancy
termination remains available. Finally, test results should
be reliable and valid.1–6
Noninvasive first-trimester screening for aneuploidy is
an example of a screening test that meets these criteria. Fetal
chromosomal abnormalities are relatively common and im-
portant obstetric problems, placing a substantial burden on
the health and well-being of families and affected fetuses.
Screening with a maternal serum analyte and nuchal
translucency measurement is a relatively easy technique
that is acceptable to most patients, and the screening effi-
ciency of this process has been well validated in the litera-
ture.7,8 Although there is no curative intervention available,
parents do have the option to proceed with invasive diag-
nostic testing via chorionic villus sampling or amniocente-
sis in the event of a positive screening test result.
Measures of Screening Efficiency
To establish the accuracy of a screening or diagnostic test,
it is essential to understand how the test performs in rela-
tion to an accepted reference standard of diagnosis. To do
so, the diagnostic indices of sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) should be determined. These indices can easily be
calculated by creating a traditional 2 × 2 table, with rows
representing positive and negative test results and columns
representing the presence or absence of disease as diag-
nosed by a reference standard method (Table 1). By form-
ing a table in this manner, 4 mutually exclusive cells are
created, representing true-positive results (a), false- positive
results (b), false-negative results (c), and true-negative re-
sults (d).
Sensitivity and specificity are inherent test character-
istics that describe the performance of the screening test
in the population being studied. Sensitivity is defined as
“the proportion of people with the disease who have a pos-
itive test-result for the disease.”3 This parameter can be cal-
culated by dividing the number of patients with the disease
who test positive by the total number of patients with the
disease: sensitivity = a/(a + c), or true-positive results/total
population with the disease.
Specificity is defined as “the proportion of people
without the disease who have a negative test result.”3 Speci-
ficity can be calculated by dividing the number of patients
without the disease who actually test negative by the total
number of patients without the disease: specificity = d/(b
+ d), or true-negative results/total population without the
disease.
Tests with high sensitivity tend to perform well for
screening because they rarely miss patients who have the
disease, although sometimes at the expense of a higher
false-positive rate. Alternatively, tests with high specificity
tend to perform well for diagnosis. Highly specific tests
rarely misclassify patients as having the disease of interest
when, in reality, they do not. Highly specific tests are often
useful for confirming the diagnosis in an individual who
initially has a positive screening test result.1,3,9
The use of highly specific tests is especially necessary
when a false-positive test result can place the patient at risk
for harm. The false-positive rate for any test can be calcu-
lated by the formula 1 – specificity. In prenatal diagnosis,
the accepted false-positive rate for most sonographic mark-
ers of aneuploidy is approximately 5%. Above this thresh-
old, it is suggested that an unacceptable number of patients
would be subjected to both the emotional burden of anxi-
ety over a positive test result and the associated risk, albeit
low, of potentially invasive diagnostic testing.
The above-mentioned attributes of the sensitivity and
specificity of ideal screening and diagnostic tests are men-
tioned as broad general principles. As with most general
principles, there are exceptions. Although it is important
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Table 1. Calculating Measures of Screening Efficiency Using a 2 × 2
Table
Disease-Positive Disease-Negative
Test-Positive True-positive (a) False-positive (b)
Test-Negative False-negative (c ) True-negative (d)
Sensitivity = a/(a + c); specificity = d/(b + d); positive predictive
value = a/(a + b); and negative predictive value = d/(c + d ).
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for screening tests to pick up most cases of the disease of
interest, high specificity is essential, particularly if the dis-
ease is of relatively low prevalence. In such cases, a small
drop in specificity has a dramatic impact on the predictive
value of a positive test result. False-positive results are not
without impact for patients and also influence health care
costs. Similarly, ideal diagnostic tests must have high sen-
sitivity as well as high specificity.
Although sensitivity and specificity are inherent per-
formance characteristics of a test that may aid clinicians
with the dilemma of whether to order that particular test,
they do not provide information on how to proceed if the
result is positive. What many clinicians want to know is the
predictive value of that test or the probability that a positive
result represents an affected patient. These predictive val-
ues can be calculated by returning to our 2 × 2 table. The
PPV is defined as “the probability of disease in a patient
with a positive test result” and can be calculated by divid-
ing the number of patients who test positive and actually
have the disease (true-positive results) by the total number
of patients with a positive result: PPV = a/(a + b), or true-
positive results/total number with a positive result.
The NPV is defined as “the probability of not having
the disease when the test result is negative” and can be cal-
culated by dividing the number of patients who test nega-
tive and do not have the disease by the total number of
patients with a negative result3: NPV = d/(c + d), or true-
negative results/total number with a negative result.
A fundamental principle in understanding predictive
values is that, unlike sensitivity and specificity, the PPV and
NPV are dependent on the prevalence of the disease of
interest. Holding sensitivity and specificity constant, as the
prevalence of a disease increases, the PPV will increase and
the NPV will decrease. Conversely, as the prevalence of a
disease decreases, the PPV will also decrease whereas the
NPV will increase.1,3,5 In interpreting studies and attempt-
ing to generalize them to your population, it is then essen-
tial to understand both the setting of the research as well as
the characteristics of the population being studied. For ex-
ample, a study of a new sonographic marker of trisomy 21
in a high-risk referral center of patients all older than 35
years may yield a PPV that is quite high, but when this same
marker is tested in a low-risk community setting, one may
find a substantial decrease in its predictive value, which
could limit the utility of this new marker in this type of pa-
tient population.
A practical application of these test performance char-
acteristics can be observed in a study by Odibo et al,10
which compared the efficiency of second-trimester nasal
bone hypoplasia to increased nuchal fold in screening for
Down syndrome. To calculate the diagnostic indices, 2 ×
2 tables were constructed with the rows representing the
presence or absence of the sonographic marker of interest
(eg, nasal bone present or nasal bone absent) and the
columns representing the presence or absence of Down
syndrome, diagnosed by the reference standard method of
fetal or neonatal karyotyping. An absent nasal bone yielded
sensitivity of 29% and specificity of 99%, whereas a nasal
bone measuring less than 0.75 multiples of the median
yielded higher sensitivity of 47% at the expense of lower
specificity of 94%. Considering the 2 × 2 table, we can see
why this finding is true. An absent nasal bone was present
in 14 (a) of 49 (a + c) cases of Down syndrome, whereas
the less discriminatory definition of a nasal bone measure-
ment of less than 0.75 multiples of the median was found
in 23 (a) of 49 (a + c) cases of Down syndrome, thereby
yielding higher sensitivity. However, given that the defini-
tion of a nasal bone measurement of less than 0.75 multi-
ples of the median is less discriminatory, this finding was
also observed in a higher proportion of patients who did
not have Down syndrome compared to the more discrim-
inatory finding of an absent nasal bone, thereby yielding
lower specificity.
The study by Odibo et al10 also shows the effect of dis-
ease prevalence on predictive values. Given that the study
cohort was of “mixed risk” for aneuploidy, a stratified analy-
sis was then performed after dividing the population into
high- and low-risk groups based on referral for the indica-
tion of maternal age older than 35 years. The prevalence
of Down syndrome was 1.8% in the high-risk group com-
pared to 0.49% in the low-risk group. Using a nasal bone
measurement of less than 0.75 multiples of the median as
an example, we can see that the PPV was higher (12%) in
the high-risk group compared to the low-risk group (3%).
Likelihood Ratios to Refine Risk
Likelihood ratios are another measure of screening effi-
ciency commonly reported in the prenatal diagnostic lit-
erature and serve a function similar to that of predictive
values. Unlike predictive values, likelihood ratios can be
used across varying ranges of disease prevalence and can
actually be practically used to alter an individual patient’s
risk for a given condition. Likelihood ratios are reported
separately for positive and negative results and are defined
as “the ratio of the likelihood of that result in someone with
the disease to the likelihood of that result in someone with-
out the disease”.3 A likelihood ratio of 1.0 indicates that the
test result is nondiscriminatory in determining those with
the disease and those without. Likelihood ratios can be cal-
J Ultrasound Med 2011; 30:1121–1127 1123
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culated if both the sensitivity and specificity of a test are
known: positive likelihood ratio = sensitivity/(1 – specificity),
or theproportion of affected individuals with a positive result/
proportion of unaffected individuals with a positive result;
and negative likelihood ratio = (1 – sensitivity)/specificity, or
the proportion of affected individuals with a negative result/
proportion of unaffected individuals with a negative result.
After a likelihood ratio is calculated, it can then be
multiplied by a patient’s pretest odds of having the disease
to determine the patient’s posttest odds of having the dis-
ease (PPV). In other words, a likelihood ratio can be used
to alter an individual patient’s a priori risk for having the
disease or outcome of interest. The further the likelihood
ratio is from 1.0 (in either direction), the greater the effect
of the test result on the individual’s posttest probability of
having or not having the disease of interest. Of note, the
equation to calculate posttest probability actually requires
the use of odds rather than probability; therefore, pretest
probability must first be converted to odds and then
posttest odds converted back to probability3,5,6,11: odds =
probability of the event/(1 – probability of the event); and
probability = odds/(1 + odds).
Again, these concepts can best be explained using an
example. In 2001, Nyberg et al12 published a study that
used likelihood ratios to estimate the degree of risk of iso-
lated second-trimester sonographic markers for the detec-
tion of trisomy 21. The marker of nuchal thickening (≥5
mm) had the highest likelihood ratio of 11.0, meaning that
the presence of this marker on second-trimester sonogra-
phy was 11 times more likely to be found in a fetus with tri-
somy 21 than in a fetus without trisomy 21. In clinical
practice, this finding could mean that a patient could pres-
ent with a theoretical age-related risk of 1 per 1000 for tri-
somy 21. If the finding of nuchal thickening is observed
during second-trimester sonography, it would raise her risk
of trisomy 21 to 1 per 91 (1/1000 × 11.0 = 1/91). These
results may substantially influence this patient’s decision
of whether to undergo amniocentesis. This example illus-
trates how a sonographic marker could increase the
posttest odds of a young patient. Alternatively, an older pa-
tient with high pretest odds (eg, 1 per 168) can have lower
posttest odds if no notable sonographic marker is present.
In the latter scenario, it is more complex to calculate the
posttest odds because the individual markers that are ab-
sent have specific negative likelihood ratios. Computerized
software in sonographic reporting packages is helpful in
these situations when patients want specific risk calcula-
tions. Alternatively, another report by Nyberg et al13 sug-
gested using a likelihood ratio of 0.4 when a normal
sonographic finding is obtained. For the above example,
the posttest odds after a normal sonographic finding would
be 1/168 × 0.4 = 1/420.13 Conveniently, obstetricians typ-
ically discuss aneuploidy risk in terms of odds; therefore,
conversion back and forth between odds and probability is
unnecessary for these particular calculations.
Determining a Threshold for a Screening
Test: The Receiver Operating Characteristic
Curve
Up to this point, we have discussed the calculation of
screening test efficiency measures using dichotomous test
results. In reality, many tests used in clinical medicine yield
results that fall on a continuum; therefore, a threshold for
what is considered positive or negative needs to be deter-
mined. In the field of prenatal diagnosis, this issue may be
relevant in determining the threshold at which an umbilical
artery pulsatility index is considered elevated or at which a
femur or humerus diaphysis length is considered shortened.
To establish these thresholds or cutoffs, a receiver operat-
ing characteristic (ROC) curve can be used. To create an
ROC curve, the sensitivity and false-positive rates of several
different potential threshold values are plotted (sensitivity
on the y-axis and 1 – specificity [false-positive rate] on the
x-axis). By creating this curve, one can visualize the trade-off
between sensitivity and specificity at each cutoff point.
Often, the inflection point (or shoulder) of the graph is cho-
sen as the cutoff value because at this value, there are an
equal number of false-positive and -negative results.3,11 In
reality, the chosen threshold should depend on the purpose
of the test of interest. As mentioned earlier, a screening test
should miss as few cases of a disease as possible; therefore,
choosing a threshold with high sensitivity, possibly at the
expense of a higher false-positive rate, may be warranted.
Choosing a threshold with a low false-positive rate at the
expense of a lower sensitivity may be more appropriate for
a confirmatory diagnostic test.1,6,9
An example of establishing thresholds using an ROC
curve can be observed in a study by Mari et al,14 which eval-
uated the value of peak systolic velocity in the middle cere-
bral artery for the detection of fetal anemia in cases of
maternal alloimmunization. Sensitivity values and false-
positive rates of various peak systolic velocities in the mid-
dle cerebral artery were plotted for the detection of mild,
moderate, and severe anemia. Because the goal of this par-
ticular screening test would be to not miss any cases of
moderate or severe fetal anemia, the threshold at which
sensitivity reached 100% was chosen, corresponding to
1.50 multiples of the median for moderate anemia and 1.55
for severe anemia. To achieve 100% sensitivity, the authors
Goetzinger and Odibo—Prenatal Diagnostic Imaging Studies: Screening and Diagnostic Tests
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had to accept a higher false-positive rate of approximately
12% (Figure 1).
Not only can an ROC curve be useful in establishing
thresholds for positive and negative test results, but it can
also evaluate the overall accuracy of the test. In general, a
test that performs well will have an ROC curve that falls
near the top left corner of the graph, whereas a test that
performs poorly will have an ROC curve that falls closer to
the 45° diagonal line (Figure 2). One can then calculate
the area under the curve (AUC), which will provide a nu-
meric value for the overall accuracy of the test. For refer-
ence, an AUC of 1.0 indicates a perfect test, whereas an
AUC of 0.5 indicates a test that performs no better than
chance. Because the AUC is a measure of test accuracy, it
can also be used to compare different screening or diag-
nostic tests, with the higher AUC representing the more
accurate test in the comparison.6,9,11
Returning to our previous example of using nasal bone
hypoplasia as a second-trimester marker of aneuploidy, a
study by Odibo et al15 evaluated the test performance char-
acteristics of various definitions of nasal bone hypoplasia
and then used these characteristics to construct an ROC
curve (Figure 3A). The definition of a biparietal diameter
to nasal bone ratio of greater than 11 provided the optimal
trade-off between sensitivity and specificity, although at
the cost of a 15% false-positive rate compared to the 7%
false-positive rate observed using a biparietal diameter to
nasal bone ratio of greater than 12. The AUC was 0.7761,
correlating with the overall accuracy of nasal bone hy-
poplasia alone as a marker of fetal aneuploidy. Figure 3B
shows a similar ROC curve, although this curve incorpo-
rates various definitions of nasal bone hypoplasia com-
bined with other markers of trisomy 21. When combining
nasal bone hypoplasia with other markers, one can see that
the overall screening efficiency increases (AUC = 0.8089).
Using the AUC to compare test accuracy is most valu-
able when comparing ROC curves that do not cross at any
point. Comparing two curves that cross at one or more
points becomes more complicated because two such
curves can actually have the same AUC value. Despite hav-
ing the same AUC value, one curve may have higher false-
positive rates for a particular range of values and lower
false-positive rates for another range.16 Rather than merely
comparing AUC values for these types of curves, the use
of “partial-area” indices has been suggested. These partial-
area indices restrict the comparison to a range of sensitiv-
ity values or false-positive rates that are most clinically
relevant to the question at hand.17,18 An even more re-
strictive approach is to compare ROC curves at a prese-
lected value for either sensitivity or the false positive rate.
This approach has not been well accepted in the literature
for two main reasons. First, it is uncommon for clinicians
and researchers to actually agree on a single value at which
to compare screening or diagnostic tests. Second, there is
a theoretical conflict over comparing ROC curves on the
basis of a single value.19 When evaluating the literature, it
is essential to know not only which type of index is being
used for comparison but also the advantages and disad-
vantages of the method.
The AUCs of several ROC curves can be compared
statistically by scrutinizing the 95% confidence intervals of
the individual AUCs. A simple approach is to consider the
ROC curves to be significantly different if the 95% confi-
J Ultrasound Med 2011; 30:1121–1127 1125
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Figure 1. Receiver operating characteristic curves for the peak systolic
blood flow velocity in the middle cerebral artery for the prediction of mild,
moderate, and severe fetal anemia. Reproduced with permission from
Mari et al.14
Figure 2. Receiver operating characteristic curve. “A” indicates inflection
point (optimal trade-off between sensitivity and specificity).
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dence intervals do not overlap. For more advanced analy-
sis including the limitations and misuses of ROC curves,
the reader is referred to works by Pepe et al20 and Cook.21
Issues in Study Design and Interpretation
Understanding these key concepts and calculations is only
one step in interpreting studies of screening and diagnos-
tic efficiency. As with any type of study, critical evaluation
of the study design and methods is necessary before im-
plementing results into clinical practice. There are multiple
ways that bias can produce falsely elevated estimates of sen-
sitivity and specificity. First, determination of disease
should ideally be obtained through a single reference stan-
dard of diagnosis. Also, positive and negative test results
should not influence how aggressively or by what means a
diagnostic workup is pursued. In addition, the test result
itself should not be part of the diagnostic criteria for the
disease of interest. Blinding is also essential, especially
when subjectivity is involved in the interpretation of a re-
sult. Those who interpret the test results should not be
aware of the diagnosis, and similarly, those who make the
diagnosis should not be aware of the test results. For ex-
ample, many consider fetal echogenic bowel to be some-
what of a subjective sonographic diagnosis. If conducting
a retrospective cohort study to determine the efficiency of
echogenic bowel for the detection of trisomy 21, those re-
viewing the sonograms and assigning a positive or nega-
tive finding of echogenic bowel should be blinded to the
actual diagnosis of trisomy 21.1,3,9,11
It is also important to consider the spectrum of pa-
tients included in the study population. A test designed to
evaluate the efficiency of a screening or diagnostic test
should encompass a broad spectrum of patients both with
and without the disease of interest. This population of
patients should be similar to the population in whom the
test would be used in clinical practice. It is important to
remember that the goal of a screening test is not to dis-
tinguish very sick patients from very healthy patients;
therefore, the study population should attempt to resem-
ble a population of patients with varying disease severities,
medical comorbidities, and even other diseases that may
closely mimic the disease of interest.3,11
Finally, to determine reproducibility, the methods of
the study should offer a detailed explanation as to how the
test was performed and by whom it was administered. The
skill level of the operator (potentially the sonographer) and
the type of institution (community center versus tertiary
care or referral center) will also influence how the results
will generalize to another population.
Studies of screening and diagnostic efficiency are typi-
cally of an observational nature and may be performed using
a range of designs, including prospective cohort, retrospec-
tive cohort, cross-sectional, case-control, and secondary
analysis of data from prior studies. Each of these designs has
its own benefits and pitfalls, which are beyond the scope of
this article. It is important to highlight that the case-control
study design cannot be used to determine predictive values
because these values are influenced by disease prevalence.
Because cases and controls are selected for inclusion, the
Goetzinger and Odibo—Prenatal Diagnostic Imaging Studies: Screening and Diagnostic Tests
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Figure 3. Receiver operating characteristic (ROC) curves evaluating the efficiency of nasal bone (NB) hypoplasia in the detection of Down syn-
drome. A, Receiver operating characteristic curve of a model using different definitions of nasal bone hypoplasia only for detection of Down syndrome. 
B, Receiver operating characteristic curve of a model using combinations of different definitions of nasal bone hypoplasia and other markers for de-
tection of Down syndrome. BPD indicates biparietal diameter. Reproduced with permission obtained from Odibo et al.15
A B
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prevalence of disease is, therefore, “fixed” by the study de-
sign. Reproducing a generalizable spectrum of patients also
becomes difficult with this type of study design.10
When evaluating screening or diagnostic tests using a
combination of variables, it is important to provide some
statistical approach to weighting of the variables because
it could improve the performance of an overall set of vari-
ables. This process is important because different compo-
nents of the set of variables may not be equally effective
predictors of the outcome of interest. One method for han-
dling this situation is by using principal components analy-
sis, which would provide the weighting factor for each
variable. Principal components analysis is a mathematical
procedure using orthogonal transformation to convert a
set of observations of possibly correlated variables into a
set of values of uncorrelated variables called principal com-
ponents. The transformation is defined to ensure that the
first principal component has as high a variance as possible
and each succeeding component in turn has the highest
variance possible under the constraint that it be uncorre-
lated with the preceding components.22 This approach has
rarely been used in obstetric imaging literature but should
be encouraged given the increasing use of multiple-para-
meter screening paradigms.
Conclusions
Studies evaluating screening and diagnostic efficiency are
common in the sonographic and prenatal diagnostic liter-
ature. This article aimed to provide an overview of some
of the key concepts frequently encountered in such stud-
ies. Whether designing your own study or analyzing results
from a study in the literature, understanding how to calcu-
late and interpret test performance characteristics in the
context of a variety of different study designs is essential to
the practical application of these results to any particular
patient population. 
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